

Business Results First Six Months of the Fiscal Year Ending March 31, 2026

Sysmex Corporation November 5, 2025

Disclaimer

- This material contains forward-looking statements about the Sysmex Group. These forward-looking statements are based on the current judgments and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations and changes in operating environments both in Japan and overseas may cause our actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements or financial position either expressed or implied within these forward-looking statements.
- The information on products and other matters contained herein is not intended as advertising or medical advice, whether or not regulatory approval has been obtained.
- The Sysmex Group adopted International Financial Reporting Standards (IFRS) in the fiscal year ended March 31, 2017. Figures are disclosed in compliance with IFRS.

Index

- 1. Executive Summary
- 2. Business results, First Six Months of the Fiscal Year Ending March 31, 2026
- 3. Growth Strategy Progress
- 4. Financial Forecast for the Fiscal Year Ending March 31, 2026

(Appendix)

1. Executive Summary

Executive Summary



Results for the First Six Months of the Fiscal Year Ending March 31, 2026

 Despite a recovery in Q2, sales and profits were down due to extraordinary factors in Q1, as well as to yen appreciation.

Year on year, net sales were down 4.1%, operating profit was down 25.9%, and profit attributable to owners of the parent as of first six months was down 26.9%

- Although sales increased in the Americas, EMEA, and AP, we restricted orders in Q1 in line with the transition to a new system in Japan. This factor, plus yen appreciation and changes in market conditions in China, led to a decline in net sales.
- Profit declined due to an inventory revaluation in Q1, a decrease in gross profit on lower sales, and a rise in SG&A expenses.
- Impact of change in the Chinese market environment expanded.
- Owing to government-driven healthcare cost control policies, sales declined due to principle of minimal necessity (restrictions on set tests) and efforts by distributors to limit inventory. Sales were down 17.9% year on year on a local currency basis.

Executive Summary



Financial Forecast for the Fiscal Year Ending March 31, 2026

Note: Figures in parentheses indicate the difference from the previous forecast.

- We have revised downward our forecasts for net sales to ¥510.0 billion (down ¥25.0 billion) and operating profit to ¥76.0 billion (down ¥15.5 billion).
 - Despite lower revenue compared to plan due to special factors in Q1, changes in market conditions in China, and delayed launch of the new growth driver, the biochemical business, overseas regions excluding China performed well, resulting in year-on-year revenue growth (+0.3%)
 - Operating profit decreased, due to the impact of special factors in Q1, although there was improvement from Q2 onward

2. Business results, First Six Months of the Fiscal Year Ending March 31, 2026


Financial Highlights (Year on Year)



(Billions of yen)		First six months of fiscal year ending March 31, 2026		First six months of fiscal year ended March 31, 2025		YoY (Previous period = 100%)
		Results	Ratio	Results	Ratio	
	Net sales	232.5	100%	242.4	100%	95.9%
	Cost of sales	109.9	47.3%	111.1	45.9%	98.9%
	SG&A expenses	77.8	33.5%	72.3	29.8%	107.6%
	R&D expenses	13.2	5.7%	15.2	6.3%	86.6%
	Other income (expenses)	1.4	0.6%	0.8	0.3%	180.8%
	Operating profit	32.9	14.2%	44.5	18.4%	74.1%
	Profit attributable to owners of the parent	19.0	8.2%	26.0	10.7%	73.1%



- Operating profit: Profit declined as a result of reduced gross profit stemming from the revaluation of inventories and lower sales in Q1, yen appreciation, as well as an increase in SG&A expenses.
 - ✓ Forex impact: Sales: ¥4.84 billion, SG&A expenses: ¥0.88 billion, operating profit: ¥1.59 billion
 - ✓ At the rates prevailing one year earlier: Sales down 2.1%; SG&A expenses up 8.8%; operating profit down 22.4%
- Profit attributable to owners of the parent as of first six months: Profit fell 26.9%. Foreign exchange gain (loss): Loss of ¥0.68 billion (YoY up ¥3.34 billion)



	First six months of fiscal year ending March 31, 2026	First six months of fiscal year ended March 31, 2025
1USD	¥146.0	¥152.6
1EUR	¥168.1	¥166.0
1CNY	¥20.3	¥21.2

Q2 Performance (Vs. Q1)



Profitability improved significantly from Q1,driven by a recovery in reagent sales in Japan and revenue growth across other regions.


	Q1 of fiscal year ending March 31, 2026 (April–June)		Q2 of fiscal year ending March 31, 2026 (July-September)	
lions of yen)	Results	Ratio	Results	Ratio
Net sales	105.7	100%	126.7	100.0%
Cost of sales	51.2	48.5%	58.7	46.3%
SG&A expenses	38.2	36.2%	39.5	31.2%
R&D expenses	6.4	6.1%	6.7	5.4%
Other income (expenses)	0.8	0.8%	0.6	0.5%
Operating profit	10.6	10.1%	22.3	17.6%
Profit attributable to owners of the parent	4.5	4.3%	14.4	11.4%

Breakdown of Net Sales (by Business and Field)



Sales by Business and Field

(Billions of yen)



Performance was positive in the urinalysis field, but main fields decreased due to the impact from Japan and China.

	First six months of fiscal year ending March 31, 2026		YoY (Previous period = 100%)	
Results	Ratio	Yen basis	Excluding FX impact	
232.5	100.0%	95.9%	97.9%	
140.5	60.5%	94.6%	96.8%	
1.6	0.7%	101.3%	102.4%	
20.6	8.9%	105.8%	108.8%	
35.1	15.1%	95.5%	97.7%	
10.2	4.4%	87.7%	89.8%	
1.2	0.6%	72.6%	74.1%	
10.1	4.4%	96.2%	95.7%	
11.2	4.8%	109.4%	109.4%	
230.9	99.3%	95.9%	97.9%	
ss 1.5	0.7%	91.9%	91.9%	
	year ending M Results 232.5 140.5 1.6 20.6 35.1 10.2 1.2 10.1 11.2 230.9	Results Ratio 232.5 100.0% 140.5 60.5% 1.6 0.7% 20.6 8.9% 35.1 15.1% 10.2 4.4% 1.2 0.6% 10.1 4.4% 11.2 4.8% 230.9 99.3%	year ending March 31, 2026 (Previous per yen basis) Results Ratio Yen basis 232.5 100.0% 95.9% 140.5 60.5% 94.6% 1.6 0.7% 101.3% 20.6 8.9% 105.8% 35.1 15.1% 95.5% 10.2 4.4% 87.7% 1.2 0.6% 72.6% 10.1 4.4% 96.2% 11.2 4.8% 109.4% 230.9 99.3% 95.9%	


Breakdown of Net Sales (by Destination and Product Type)



Sales rose in the Americas, EMEA, and AP, but net sales were down overall, owing to decreases in Japan and China


		First six months of fiscal year ending March 21, 2026		period = 100%)
(Billions of yen)	Results	Ratio	Yen basis	Local currency basis
Net sales	232.5	100.0%	95.9%	97.9 % [*]
America	s 64.6	27.8%	101.5%	105.9%
EMEA	72.9	31.4%	105.6%	104.2%
China	43.2	18.7%	79.4%	82.1%
AP	26.1	11.2%	105.7%	108.7%*
Japan	25.4	10.9%	83.9%	-
Instrumer	nts 43.8	18.9%	92.2%	93.8%
Reagents	147.5	63.5%	97.9%	100.1%
Services	32.2	13.9%	96.7%	99.1% *
Others	8.8	3.8%	81.2%	81.9% _*

^{*}Year-on-year increase on a yen basis, excluding the impact of exchange rate fluctuations



Major Reasons for Changes by Destination Note: On a local currency basis


Americas	Favorable performance in North America continued on from Q1, and performance rose substantially in Central and South America in Q2. In Q2 alone, sales rose 8.8% year on year.
EMEA	 Despite revenue declined in Turkey and Saudi Arabia due to geopolitical impacts in the Middle East, both instrument and reagent sales remained strong in major countries, resulting in an overall sales increase.
China	 In addition to the impact of healthcare cost control policies (principle of minimal necessity), inventory adjustment due to deteriorating distributor finances, resulting in a decline in sales.
AP	Sales of hematology reagents recovered, centered on India. In Southeast Asia, sales of hematology and urinalysis reagents grew, resulting in overall sales growth.
Japan	 Although sales declined in comparison with strong instrument sales in the previous fiscal year and temporary order constraints in Q1 associated with the transition to a new core system, in Q2 reagent sales returned to normal levels.



Information by Destination (Americas)



	First six months of fiscal year	of fiscal year	YoY (Previous period = 100%)	
(Million USD)	ending March 31, 2026	ended March 31, 2025	Local currency basis	Yen basis
Net sales	442.7	417.8	105.9%	101.5%
Instruments	98.2	88.9	110.5%	105.9%
Reagents	220.6	212.3	103.9%	99.5%
Services, others	123.7	116.5	106.2%	101.7%



Favorable performance in North America continued on from Q1, and performance rose substantially in Central and South America in Q2. In Q2 alone, sales rose 8.8% year on year.

Instruments

- ✓ Instrument sales increased, owing to favorable performance in the hematology, urinalysis, and hemostasis fields.
- ✓ In 2H, we expect the launch of new products to boost revenue further.


Reagents

- ✓ Reagent sales grew, owing to steady performance in the hematology, urinalysis fields.
- Amyloid β test reagents continued to show solid growth.
 (sales of USD3.4 million, up 60% YoY)
- ✓ In the hemostasis field, we anticipate revenue growth from the increased equipment sales going forward.

Information by Destination (EMEA)



	of fiscal year	First six months of fiscal year	YoY (Previous period = 100%)	
(Million EUR)	ending March 31, 2026	ended March 31, 2025	Local currency basis	Yen basis
Net sales	434.0	416.5	104.2%	105.6%
Instruments	95.7	91.9	104.2%	105.7%
Reagents	273.8	260.8	104.9%	106.3%
Services, others	64.4	63.6	101.3%	102.3%



Despite sales declines in Turkey and Saudi Arabia due to geopolitical impacts in the Middle East, both instrument and reagent sales remained strong in major countries, resulting in an overall sales increase.

Instruments

- ✓ Instrument sales were up. The XR[™]-Series performed strongly in France and Northern Europe, while urinalysis sales grew in Italy and Spain.
- ✓ We anticipate growth in the hemostasis field, supported by the acquisition of major tenders, including the CNTM -Series, in Germany..

Reagents

✓ Despite declines in Turkey and Saudi Arabia, performance in key countries remained solid, resulting in sales growth across all fields.

Note: Sales in Russia have been excluded, including for past years.

Information by Destination (China)



	First six months of fiscal year ending	First six months of fiscal year ended	YoY (Previous period = 100%)	
(Million CNY)	March 31, 2026		Local currency basis	Yen basis
Net sales	2,126.6	2,590.8	82.1%	79.4%
Instruments	248.5	344.6	72.1%	70.0%
Reagents	1,659.0	1,894.0	87.6%	84.6%
Services, others	219.0	352.0	62.2%	60.5%

Sales (Million CNY) 2,590 2,479 2,399 352 258 2,145 2,126 257 344 227 Services, others 394 589 248 Instruments 383 1,894 1,747 1,659 1,632 Reagents 1,535 2022 2023 2024 2025 2026 (First six months of years to March 31)

In addition to the impact of healthcare cost control policies (principle of minimal necessity), inventory adjustment due to deteriorating distributor finances, resulting in a decline in sales.

Instruments

- ✓ In hematology, the installed instrument base in high-end markets remained flat year on year. In mid- and low-end markets, compact models performed well; however, instrument sales declined due to distributor inventory adjustment.
- ✓ Sales continued to rise in the hemostasis and immunochemistry fields, with favorable performance sustained from 2H of the previous year, supported by the impact of knockdown production.

Reagents

- ✓ Due to the principle of minimal necessity, the market has seen a reduction in CRP tests and the number of tests in hemostasis tests.
- ✓ Worsening financial conditions led distributors to reduce inventories, lowering our reagent sales.

The Business Environment in China




Our hematology business situation

Maintaining market share* in a highly competitive environment



^{*} Calculations reflect our own estimates based on disclosed information.

Number of tests/units down slightly



Number of units installed in the market (First six months of fiscal year ending March 31, 2026)

: Equivalent to the previous fiscal year High-end

Middle-end: Locally produced XNTM-L Series performed well

Impact of healthcare cost control policies becoming apparent

Principle of minimal necessity (restriction on bundled testing)


The Chinese government has required medical institutions at Tier two and above to review their set testing items in accordance with the principle of minimal necessity.

Impact to Sysmex became apparent.

- The number of CRP test decreased.
- The number of Hemostasis test (D-Dimer, disposables) decreased.

Deterioration in the financial condition of medical institutions and distributors

Healthcare cost control policies




Medical institution

Many are running at a loss

Outlooks for this Fiscal year in China



We have carefully examined changes in the market environment and the impact of various policies, and have revised our outlook for this fiscal year



Outlook for this fiscal year

- The impact of the principle of minimal necessity persists, but the downturn driven by various policies is expected to run its course by the end of this fiscal period.
- Inventory adjustments by distributors are expected to bottom out between the 3Q and 4Q

Countermeasures


- Strengthening direct outreach to target customers to replace competitors
- Promoting proposals for fully automated system products
- Expanding our product portfolio

Information by Destination (AP)



(Billions of yen)	First six months of fiscal year ending March 31, 2026		YoY (Previous period = 100%) Yen basis
Net sales	26.1	24.7	105.7% (108.7%)
Diagnostics business	26.0	24.7	105.3%
Instruments	4.5	5.0	90.4%
Reagents	19.4	16.8	114.9%
Services, others	2.0	2.7	74.7%
Medical robotics business	0.08	-	-

Note: Figures in parentheses exclude the impact of exchange rate fluctuations



Although Sales of instrument decreased, Sales of hematology and urinalysis reagents grew, boosting 1H sales. In Q2 single, growth in sales of hematology reagents in Indonesia drove double-digital sales growth.

Diagnostics business

Instruments

✓ Sales declined due to factors such as budget constraints on medical instruments in Indonesia.

Reagents

✓ Sales rose, supported by a recovery in hematology reagents in India, as well as growth in sales of hematology and urinalysis reagents across Southeast Asian countries including the Philippines.


Medical robotics business

- ✓ One unit was installed in 1H, raising the total number of units installed to four.
- ✓ The number of surgeries is increasing steadily, with more than 100 performed in both Singapore and Malaysia.

Information by Destination (Japan)




(Billions of yen)	First six months of fiscal year ending March 31, 2026	First six months of fiscal year ended March 31, 2025	YoY (Previous period = 100%) Yen basis
Net sales	25.4	30.3	83.9%
Diagnostics business	23.9	28.6	83.7%
Instruments	3.3	5.7	57.7%
Reagents	16.1	18.2	88.8%
Services, others	4.4	4.6	95.5%
Medical robotics business	1.4	1.7	87.1%



Sales of reagents declined due to the impact of strong instrument sales in the previous fiscal year and temporary order constraints in Q1 associated with the transition to a new core system. However, reagent sales have returned to normal levels.

Diagnostics business

- ✓ Instrument sales were down, mainly due to comparison with strong sales in the previous fiscal year, particularly in hematology.
- ✓ In reagents, the impact of order restrictions has largely been resolved. Sysmex took market share from competitors in the hematology and hemostasis fields.




Medical robotics business

- Due to weak capital investment by hospitals, the number of installation declined.
- 6 units were installed in 1H, bringing the total to 92 (96 globally)

Breakdown of Operating Profit (Year on Year)



Operating Profit




Note: Figures and comments below exclude the impact of exchange rates.


- Fluctuation in gross profit due to changes in net sales: ¥2.76 billion
- Impact of change in the cost of sales ratio: ¥3.51 billion (1.4pt deterioration)
 - ✓ Positive factor: Improved logistics costs, 0.1 pt
 - ✓ Negative factors: Impact of inventory revaluation, 0.7 pt; Worsening service costs, 0.7pt; tariff impact, 0.2 pt
- Higher SG&A expenses: ¥4.96 billion
 - ✓ Labor costs rose approx. ¥2.4 billion, due to personnel increases owing to expansion of the direct sales area, as well as higher unit costs.
 - ✓ Other costs rose approx. ¥1.4 billion in line with an increase in scale and sales promotion activities.
- Increase in depreciation expenses: ¥1.42 billion
- Lower R&D expenses: + ¥2.03 billion
 - ✓ While investment in product development continues, total R&D expenses declined due to prioritization and narrowing of research themes following a strategic pivot in the life sciences field.
- Change in other operating expenses: ¥0.67 billion
- FX impact: -¥1.59 billion

Breakdown of Changes in the Consolidated Statement of Financial Position




On the asset side, trade and other receivables declined, while inventories increased. In liabilities and equity, while current liabilities declined due to corporate tax payments, other equity increased primarily due to the impact of foreign exchange fluctuations.





Consolidated Cash Flows





3. Growth Strategy Progress

Reinforcement of Existing Businesses, Emerging Market Strategies, Expansion of New Businesses

Market Expansion in the Clinical Chemistry Field



Biochemistry is a fundamental test and essential for the establishment of laboratories. In both advanced and emerging markets, growing demand for screening tests is driving the formation of a sustainable growth market.


■ Scale of the IVD Market (By Field)

Field	2024 market size (million USD)	Market growth rate (2025–2028)
IVD overall	96,000	3%
Immunochemistry	27,000	3%
Clinical chemistry	9,000	4%
Hematology	4,300	3%
Hemostasis	3,200	3%
Urinalysis	1,200	3%

Note: The market size and growth rate of the IVD market and each testing field (as of 2024) are estimates calculated by Sysmex based on publicly available information.

Increasing customer expectations for Sysmex in clinical chemistry

■ Market Growth Forecast by Country in the Clinical Chemistry Field



Source: Kalorama 30-Country In Vitro Diagnostics(IVD) Market Atlas[2024]

Emerging market are projected to achieve higher growth rates.

Objectives of Acquiring the Clinical Chemistry Testing Business from JEOL



- Combine JEOL's instrument technology with Sysmex's strengths to deliver solutions—including reagents and quality control—mainly to emerging markets.
- Adding clinical chemistry enables full coverage of key laboratory tests and leverages data and Al to deliver diverse value.

1. JEOL's instrument features

- Minimal sample and reagent requirements through proprietary sample dilution technology
- Achieves high throughput
- Top market share in Japan

2. Immediate prioritized regions

Japan, Emerging markets, China (Collaboration with WEGO Medical)



already sold by us in some countries: BioMajesty™ JCA-BM6010

3. The scheduled closing date

April 1, 2026 (Progress is proceeding, including obtaining clearance from the Japan Fair Trade Commission)

Business Expansion Image in Clinical Chemistry



Through delivering our proprietary products and services tailored to customer needs, we aim to capture testing demand in emerging markets and realize growth and enhanced profitability in clinical chemistry.

Instrument

Synergies from the acquisition of JEOL's clinical chemistry business

Manufacturing

- Economies of scale through increased production volume
- Cost reduction by leveraging our manufacturing capabilities and supply chain

Significant reduction in COS

Development

- Compact instruments for emerging markets
- Test integration utilizing transportation connectivity



*Image

Develop initiatives to meet customer needs

Reagent

Develop partnerships with reagent manufacturers to accelerate global reagent sales (including OEM arrangements)


 Ensuring profitability through the synergistic effect of global expansion of unique items and the benefits of minimal sample measurement

Quality Control Service

Global Expansion of Quality Control System (Caresphere™)

Three Growth Strategies: Emerging Market Strategies





- We are expanding our direct sales and service territories from major metropolitan areas into suburban areas, aiming to further increase market share in the upper-mid segment by leveraging our strengths in laboratory efficiency solutions.
- In emerging markets such as Egypt and Turkey, growing demand for laboratory efficiency is driving the adoption of Blood Science, an integrated system combining hematology and hemostasis.





Stories

How Testing Empowers Healthcare: Sysmex's New Challenges in Hemostasis Testing Across EMEA

https://www.sysmex.co.jp/en/stories/hemostasis-testing-business-revolution.html

Key Initiatives

^{*}META: Middle East, Turkey, and Africa

Strategic Initiatives in India



Our local production system, established in response to "Make in India," is operating smoothly, and product shipments have begun.


- At our new production site, the manufacture of instruments and reagents is progressing smoothly, and shipments of reagent products have begun.
- For instruments, we aim to achieve 50% local content
 (Class I*) by the end of the fiscal year to March 31, 2026.





* Class I: Minimum of 50% local content (eligible for preferential treatment in bidding) Class II: Minimum of 20% local content (eligible for participation in Make in India tenders) (Based on Sysmex's research) Improving local healthcare challenges and adapting to market environments with strategic product launches and new value propositions

- Launch the first strategic product that leverages IT/digital technologies to support the operation of testing systems and provide appropriate services
- Collaborate with public and private sectors to create new solutions using our unique testing data to address public health and local healthcare challenges (aiming for release by the next fiscal year)




Three Growth Strategies: Expansion of New Businesses (Medical Robotics Business)



Establishing a stable revenue base through an increase in the number of surgeries, driven by expansion of installed unit base

- ✓ Japan: Thanks to coverage across a broad range of clinical departments and an increase in the number of installed units, the number of surgeries grew approximately 150% year on year.
 - AP: The number of surgeries increased year on year. With a growing track record and enhanced reliability, efforts are underway to accelerate further adoption in neighboring countries.
- ✓ Europe: We aim to obtain regulatory approval within the current fiscal year and advance the establishment of a market launch framework.





Medicaroid Opens Training Center at IRCAD France

4. Financial Forecast for the Fiscal Year Ending March 31, 2026

Revised Financial Forecast for the Fiscal Year Ending March 31, 2026



Green text indicates changes from initial forecast (May 2025)

Due to the deteriorating business environment in China, both net sales and operating profit forecasts have been revised downward.

1H of fiscal year ending March 31, 2026 (April–September)			March	31, 2026	Fiscal year ending March 31, 2026 (April–March)				
Results	Ratio	Vs. forecast	Revised forecast	Ratio	Revised forecast	Ratio	УоУ	Vs. initial forecast	
232.5	100%	96.9%	277.5	100.0%	510.0	100.0%	100.3%	-25.0	
109.9	47.3%	-	131.5	47.4%	241.5	47.4%	102.0%	-9.5	
77.8	33.5%	-	85.6	30.9%	163.5	32.1%	108.4%	+2.5	
13.2	5.7%	-	16.8	6.1%	30.0	5.9%	95.4%	-3.0	
1.4	0.6%	-	(0.5)	-	1.0	0.2%	(46.7)%	-0.5	
32.9	14.2%	91.5%	43.0	15.5%	76.0	14.9%	86.8%	-15.5	
		amortiz	zation:	ROE	9.5%	-			
	Results 232.5 109.9 77.8 13.2 1.4 32.9 Capital expe	March 31, 2026 (April–September Results Ratio 100% 109.9 47.3% 77.8 33.5% 13.2 5.7% 1.4 0.6%	March 31, 2026 (April–September) Results Ratio Vs. forecast 232.5 100% 96.9% 109.9 47.3% - 77.8 33.5% - 13.2 5.7% - 1.4 0.6% - 32.9 14.2% 91.5% Capital expenditure: Deprecia amortization	March 31, 2026 (April–September) March (Octobe) Results Ratio Vs. forecast Revised forecast 232.5 100% 96.9% 277.5 109.9 47.3% - 131.5 77.8 33.5% - 85.6 13.2 5.7% - 16.8 1.4 0.6% - (0.5) 32.9 14.2% 91.5% 43.0	March 31, 2026 (April–September) March 31, 2026 (October–March) Results Ratio Vs. forecast Revised forecast Ratio 232.5 100% 96.9% 277.5 100.0% 109.9 47.3% - 131.5 47.4% 77.8 33.5% - 85.6 30.9% 13.2 5.7% - 16.8 6.1% 1.4 0.6% - (0.5) - 32.9 14.2% 91.5% 43.0 15.5% Capital expenditure: Depreciation and amortization:	March 31, 2026 (April-September) March 31, 2026 (October-March) Results Ratio Vs. forecast Revised forecast Ratio Revised forecast 232.5 100% 96.9% 277.5 100.0% 510.0 109.9 47.3% - 131.5 47.4% 241.5 77.8 33.5% - 85.6 30.9% 163.5 13.2 5.7% - 16.8 6.1% 30.0 1.4 0.6% - (0.5) - 1.0 32.9 14.2% 91.5% 43.0 15.5% 76.0 Capital expenditure: Depreciation and amortization:	March 31, 2026 (April–September) March 31, 2026 (October–March) March 31, 2026 (October–March) March 31, 2026 (April–September) March 31, 2026 (October–March) Revised forecast Ratio 232.5 100% 96.9% 277.5 100.0% 510.0 100.0% 109.9 47.3% - 131.5 47.4% 241.5 47.4% 77.8 33.5% - 85.6 30.9% 163.5 32.1% 13.2 5.7% - 16.8 6.1% 30.0 5.9% 1.4 0.6% - (0.5) - 1.0 0.2% 32.9 14.2% 91.5% 43.0 15.5% 76.0 14.9%	March 31, 2026 (April-September) March 31, 2026 (October-March) March 31, 2026 (April-September)	

Assumed Exchange Rates

7 100001110 41 =1101	Full year	Full year	Second half
	(Announced May 2025)	(Revised November 2025)	(Revised November 2025)
1 USD	¥142.0	¥148.5	¥151.0
1 EUR	¥160.0	¥171.5	¥175.0
1CNY	¥19.5	¥20.8	¥21.3

Exchange Rate Sensitivity (2H)

	Net sales	Operating profit
USD	¥0.41 billion	¥0.05 billion
EUR	¥0.31 billion	¥0.01 billion
СNУ*	¥0.23 billion	¥0.15 billion

*Per ¥0.1 change 30

Financial Forecast for the Fiscal Year Ending March 31, 2026 Sysmex (Sales by Business, Field, and Destination)



Sales by business and field

(Billions of yen)

	FY03/2026	YoY (Previous period = 100%)
Hematology	303.5	100.1%
FCM	5.5	151.2%
Urinalysis	44.5	109.0%
Hemostasis	78.5	95.3%
Immunochemistry	22.0	85.0%
Clinical chemistry	3.5	96.3%
Life science	24.0	112.5%
Others	23.5	104.8%
Diagnostics business	505.0	100.3%
Medical robotics business	5.0	93.1%
Total	510.0	100.3%

Sales by destination

(Billions of yen)

	FY03/2026	YoY (Previous period = 100%)
Americas	139.0	106.0%
EMEA	160.0	114.0%
China	93.5	79.3%
Asia Pacific	56.5	110.1%
Japan	61.0	90.0%

Text in green indicates revisions.

Dividend Forecast



 The dividend amount represents a ¥6 year-on-year increase (No change from the initial forecast)

	Interim dividend	Year-end dividend	Total	Payout ratio
Fiscal year ended March 31, 2025	¥15	¥17	¥32	37.4%
Fiscal year ending March 31, 2026 (forecast)	¥19 Note: Includes a ¥1 commemorative dividend	¥19 Note: Includes a ¥1 commemorative dividend	¥38	53.0%

Toward the Fiscal Year Ending March 31, 2027



Targeting Strong Revenue and Profit Growth from the Fiscal Year Ending March 31, 2026 by Leveraging Growth Factors

Growth Drivers

- Solid growth in overseas regions
 - Expansion of the hemostasis business in Europe and the U.S.
 - Continued growth in emerging markets such as India
 - Introduction of robotic-assisted surgery system in Europe
- Launch of the clinical chemistry business
- Recovery in Japan and China

- Providing New Value through Digital Solutions
 - Sysmex AI Scheduled for Release during the Fiscal Year Ending March 31, 2026
 - 1. Features of Sysmex Al



- Possesses specialized knowledge in testing and diagnosis
- ✓ Knowledge of laboratory medicine
- ✓ Large-scale receipt data and academic/testing data owned by Sysmex
- Recommends tests to improve risk estimation accuracy
 - ✓ Research parameters from Sysmex products
 - ✓ Utilization of Sysmex's proprietary biomarkers
- On-premises LLM support tailored to clinical settings
 - ✓ Secure AI that can operate without the need for an external internet connection







(Appendix)

Topics (July-October 2025)



Diagnostics business

- Sysmex Expands Portfolio and Accelerates Global Expansion through Acquisition of JEOL's Clinical Chemistry Testing Business
- Exclusive Distribution Agreement Signed in Japan for Illumina's TruSight™ Oncology Comprehensive Panel System (Japan)
- Received Partial Modification Approval for the AmoyDx[®] Lung Cancer Multi-Gene PCR Panel as the Sole Companion Diagnostic for the New Lung Cancer Drug Taletrectinib
- Standardized Measurement Procedures for Red and White Blood Cells Registered in the JCTLM International Database
- Sysmex Partners with QIAGEN for Exclusive Distribution and Supply of Clinical Diagnostic Products in Infectious Diseases and Oncology in Japan

Sustainability

- Sysmex Becomes First in the Industry to Obtain Certification for Closed-loop Recycling of Reagent Containers under the Plastic Resource Circulation Act
- Sysmex Corporation Selected as a Constituent of All ESG Indices Adopted by the GPIF
- Balancing Business Growth and Reducing Environmental Impact as the Industry's First TNFD Adopter

Published the Sysmex Report 2025 and the Sysmex Sustainability Data



Book 2025


Sysmex Report 2025 (integrated report)

https://www.sysmex.co.jp/en/ir/library/annual-reports/



Sysmex Sustainability Data Book 2025 (yearly report)

https://www.sysmex.co.jp/en/csr/report/



-	tus of Sustainabl	By Targets.										
	Malerally	011		Flural 2026	Target Found 2025	Presid 2010 (See Vision)	Franci 202	Floral 2021	Final 2002	Fixed 2023	Floral 2024	Progress and Falue Indialogs
		Number of Investigatings	Number of CEC levin		_	GAT VALUE		2,971	2,677	3,320	3,302	The consider of hermatology bridge in Noval 2028, declared do
		lenk	(instead are the manders of energe sky). Presentage of a serial shirt sales to the	_				ratios	million	milian	million	a lampone y impact from a change in apprepation methods, harantees, our lookings continues to progress faculable.
0		Hermatistings market share**	marked size of instruments, magents, and services in a single year in the field of fee makings				55.6%	544%	\$4.0%	\$3.0%	54.6%	Market share increased due to growth in reagent sales show rise to indicreased and albations across all regions, respective to memory presides such as belle and Sauch Inskir, and proper
į	Seculation of	Number of cases with perginal support relief.	Number of cours will not goal sited system. I manufactured by Medicanid Corporation.				-	-	1,323	2,913	5,259	others is safety regions. The successful of nodes into all Regular resolution in Japan and EPEA, also contributed in this grounds.
1	remitted towers drawigh	Number of sales is	Total currier of patients, altity-model	_			3.465	1460	3,832	2848	1397	Sales of surgical robot system largue overseas in Seal 2020, the combin of cases increased distribution, primarily in Spin
ž.	rmostor		rights and designing its stratered. Total number of patients, althyrecalet	-	-	-		-				she to an increase in the number of installations.
1		Number of easy patents	rights and designing its applied for				267	200	297	200	182	The number of several government and pirel and the contact of lemas several techniquesing the COM control have been should progress
- 2		Number of nature presents Analyzed **	Number of carrier governes analyzed by the NCC Countered				Trouser.	Toursed	17 thousand	16 thousand	1.8 Treaspert	The curries of poles i applications decreased as we green to a straightful in our arteston of poles is that qualitative follows.
- 5		Number of Irraed, carrier treats using the CONA.	Number of liveral narrow bedauschade		1	46	54	92	52	53	and find more shalogic polaric continuations. We will continue to recently the special impact of both our ex-	
8		refred	CINA method				Prostant	thousand	thousand	Tousand	Treesand	obagousticationiness and our new residual stimites business.
dety	Improvement in accessibility in Institutes	Lairs is everying and developing markets	Currentificated sales in everying and developing one field.			-	W122 O Billion	MHERO Billion	WS67 blisn	White billion	MTRS billion	The might have development on their states and service when the enemaging considers such as including the Middle East, Not- ard Easte Analos, safes in enemaging and disording in under increased by approximately Tabilities yet their first permissed, year. Probleming landerers approximately as not only as of our growth shading as, on any noticing in appear improves your probleming for information and goodle.
71000	Person of specify	Plantan of results ²⁻⁴	Number of solutions creatly because for products and Creat series and magnitely				8	3	7	4	6	In Based 2020, the surviver of recollar recovered by here every with the previous baselings at however, the serverse in batch houses, he for P.C. surviver, the first previous baseline, no searcing below was resourced, as in the previous baseling year. We accurately prevent defending products have entering the regarded to reduce the defending and products the resourced products and products and products are resourced to the products are resourced to the products and the products are resourced to the products and the products are resourced to the products are resourced to the products and the products are resourced to the products are resourced to the products are resourced to the products and the products are resourced to the products are resourced
and the	and in al	Number of PDA marring letters	Number of PES searcing letters insured to Dynamics				0	0	0	0	D	regulations, of mark-concelling containing regular quality activities of mark-containing observations have the mental through our gift quality compliant, have thing applicancy, and thomosphys constiguing the concern of distriction products. We will constitute an artistic form of distriction products are subject on a product to a market product and artistic of our products.
1		CSF servey response note (power's suppliers in Impercent comment)	Entrany equations in Dears, and one seast	90%	11%		89%	90%	94%	15%	10%	The CBS surveyors presented to final 2026 uses residented at 1955, continuing there the president facilities and achieved the Langel of 1955, in addition to see ting bound the improvement of
1	Sirengifeering eupplysituale rearragement	Number of Enginery services for suppliers [lapset] ²⁴	Survive of landings, business and other training sessions for domestic suppliers. [single year]	S.	6		2	S	S S	6	6	indicitive has also in the results of the CDF survey, an emphasized has improved as the CDF survey and ECP requires the sales 2020, we teld as SBF tracking section and subsely section on the
écet,		Trind yearly car lifter lier sale of suppliers. [primary_lapar]**	Percentage of provincy can material supplies a (domental) ablancing third quarty on this atom for reason behaving or product quality. Discord of around calcular of sylvanian.		-		96%	99%	96%	89%	2993	orque farue and positive of calculating green coors gas a record possessing and select far reclaims CES environs as a coordinate of the supply of last 100 and in ordinate to provide a substantial processors and ensure a stability supply of our products and receivers.
E		Zero productions	manufactured growth, resumed and spare parts. (cost/sales percentage)	0.20%	0.95	Lessthan	-	-	-	0.40%	0.40%	Acquel of our effects to advise an a product law, we relain that a recycle-grapher and exhibit regions he occurred out our exist had a soften regions he occurred out our exist. But it is a reconstruction of the dispute.
day see	Season	Broguling of containers, and parking and all last law of environment completion male talk	Bale of recycled or environmentally conscious male tals used to contain en- and partiaging falseting male tals. Percentage of reduction of green access	50%	60%	100%	-	-		43%	62%	COVE-Treatment magnetisated after them, the covered or smell distinction and the color measured of the same level as in the previous flowing two Tip hilly samelying to recepted and remains removed by the relative seal of the covered or the covere
Mar.	erodalises is product Me spale	Brain ion of green or or get employed as the green of the	gas entraions (Ecope I) selfs F12022 as Deckase year	0.45%	0.410%	0.436%	-	-	-	CHIEF	CK B	certified proper and explaining recorder patiets for lead sometic visualization of the recorded contactivity for lead 2008. With request to Economic type to be based 2008.
and in gase		Duppler engagement. selle	The percentage of expolent in Categories 1, 2, 4, and 9 Pod have obtained SET on Unitality on the convented to DHS evolution industries explosited to SET			-	-	-		40%	41%	Will be produced by promote the control of the product of the control of the cont
2		Britis item of packaging and labeling materials	Percentage reduction of hold packaging malerial mosty-transh PVZER at the lower year.				0.64%	130 9%	0178	0.49%	0.64%	reflected in the layers rewrat our largeress satisfact respons

Topics

The Sysmex Report 2024 received an award in a US annual report competition

2024 Vision Awards

Annual Report Competition

- Top 100 Worldwide Rank: 86
- PLATINUM WINNER WORLDWIDE, etc.











Together for a better healthcare journey